Impact of specific serotonin receptor modulation on restricted repetitive behaviors.

RRBS autism obsessive compulsive disorder restricted repetitive behaviors serotonin receptor

Journal

Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952

Informations de publication

Date de publication:
2022
Historique:
received: 24 10 2022
accepted: 28 11 2022
entrez: 9 1 2023
pubmed: 10 1 2023
medline: 10 1 2023
Statut: epublish

Résumé

Restricted, repetitive behaviors (RRBs) are commonly divided into two behavioral categories, lower-order and higher-order RRBs. Individuals displaying lower-order motoric RRBs may express repetitive hand flapping behaviors, body rocking back and forth movements, and continuous body spinning. Higher-order RRBs most commonly cover the behavior inflexibility and cognitive rigidity commonly found in disorders such as autism spectrum disorder and obsessive-compulsive disorder. Various neuropsychiatric disorders are plagued by RRBs yet no FDA-approved treatments have been identified. In rodents, lower-order RRBs are commonly measured through various tasks, such as repetitive self-grooming, marble burying, and stereotypic motor behaviors. This review focuses on the effects that modulation of specific serotonin receptors have on lower-order RRBs. Although there is research examining how changes in 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 receptor modulation, more research has focused on the 5-HT1A, 5-HT2A, and 5-HT2C receptors. The accumulating data suggest that increasing 5-HT1A activation decreases RRBs while blocking 5-HT1A activation has no effect on RRBs. While there are mixed findings regarding the impact of 5-HT2A modulation on RRBs, the general trend shows mixed effects of 5-HT2A receptor activation RRB expression, whereas blockade generally decreases RRBs. 5-HT2C receptor activation can modulate RRBs in either direction depending on the 5-HT2C drug used, blocking 5-HT2C activation only seems to show therapeutic properties when 5-HT2C activation is already elevated. The other 5-HT receptors have been explored far less but show promise as potential targets for regulating RRBs. Although it is less clear due to the involvement of 5-HT1D, 5-HT1A activation increases RRBs, and blocking 5-HT1A tends to decrease RRBs. 5-HT2B activation could reduce RRBs, while inhibiting 5-HT2B does not impact RRBs. Increasing 5-HT3 has not been shown to affect RRBs. Yet, increases in RRBs have been observed in Htr3a KO mice. 5-HT6 receptor activation can increase RRBs, while blocking 5-HT6 activity tends to decrease RRBs. Lastly, neither increasing or blocking 5-HT7 activity can reduce RRBs. In sum, there is no uniform pattern in whether all specific 5-HT receptors affect RRBs in either direction, instead, there is evidence suggesting that different 5-HT receptors can modulate RRBs in different directions. Further researching the less explored receptors and aiming to understand why these receptors can differently modulate RRBs, may play a key role in developing therapeutics that treat RRBs.

Identifiants

pubmed: 36620862
doi: 10.3389/fnbeh.2022.1078983
pmc: PMC9816668
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1078983

Informations de copyright

Copyright © 2022 Alvarez, Cavazos, Morales, Lopez and Amodeo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Neurochem Res. 2020 Dec;45(12):3059-3075
pubmed: 33095437
Autism Res. 2014 Oct;7(5):555-67
pubmed: 24894823
J Neurochem. 1986 Aug;47(2):529-40
pubmed: 2942638
Eur J Pharmacol. 1996 May 6;303(1-2):1-12
pubmed: 8804905
Prog Neuropsychopharmacol Biol Psychiatry. 1999 Apr;23(3):533-44
pubmed: 10378235
Behav Pharmacol. 2006 Nov;17(7):637-40
pubmed: 17021397
Annu Rev Med. 2009;60:355-66
pubmed: 19630576
Brain Res Mol Brain Res. 1992 Aug;14(4):357-62
pubmed: 1326699
Biol Psychiatry. 2006 Jul 15;60(2):192-201
pubmed: 16487942
Psychopharmacology (Berl). 1995 Sep;121(1):81-90
pubmed: 8539344
Behav Brain Res. 2016 Oct 15;313:67-70
pubmed: 27378338
Biol Psychiatry. 2005 Aug 1;58(3):226-32
pubmed: 15939406
Mol Pharmacol. 2008 Mar;73(3):748-57
pubmed: 18083778
Psychopharmacology (Berl). 2016 Jan;233(1):57-70
pubmed: 26423528
Neurosci Lett. 2007 Mar 13;414(3):247-51
pubmed: 17267119
Neuropsychobiology. 2004;50(3):200-5
pubmed: 15365215
Front Psychiatry. 2017 May 22;8:89
pubmed: 28588509
Neuropharmacology. 1995 Oct;34(10):1297-303
pubmed: 8570027
Int J Neuropsychopharmacol. 2008 Sep;11(6):811-25
pubmed: 18339223
Br J Pharmacol. 2015 Mar;172(5):1305-18
pubmed: 25363799
Kaohsiung J Med Sci. 2013 Jul;29(7):362-7
pubmed: 23768699
Neuropsychopharmacology. 1998 Nov;19(5):354-64
pubmed: 9778658
J Clin Invest. 2013 Dec;123(12):4986-91
pubmed: 24292660
Gen Pharmacol. 1997 Apr;28(4):583-7
pubmed: 9147028
Pharmacol Biochem Behav. 1997 Aug;57(4):897-908
pubmed: 9259022
Psychopharmacology (Berl). 1997 Feb;129(4):365-71
pubmed: 9085406
Behav Pharmacol. 2008 Mar;19(2):145-52
pubmed: 18332679
Pharmacol Biochem Behav. 1997 Jan;56(1):41-6
pubmed: 8981607
Eur J Pharmacol. 2004 Mar 8;487(1-3):125-32
pubmed: 15033384
Eur J Pharmacol. 2014 Nov 5;742:94-101
pubmed: 25199966
Eur J Neurosci. 2000 Sep;12(9):3239-49
pubmed: 10998107
Jpn J Pharmacol. 1995 May;68(1):65-70
pubmed: 7494384
Brain Res Bull. 2000 Apr;51(6):499-505
pubmed: 10758340
Psychopharmacology (Berl). 2014 Mar;231(6):1191-200
pubmed: 23975037
J Autism Dev Disord. 2009 Apr;39(4):572-88
pubmed: 19037716
Front Neurosci. 2019 Jan 22;12:1043
pubmed: 30723393
Eur J Pharmacol. 2008 Sep 11;592(1-3):103-8
pubmed: 18644366
Genes Brain Behav. 2017 Mar;16(3):342-351
pubmed: 27717169
Ann N Y Acad Sci. 1990;600:132-47; discussion 347-48
pubmed: 2252306
Neuropharmacology. 2018 Mar 15;131:104-115
pubmed: 29225044
Mol Pharmacol. 2003 Dec;64(6):1295-308
pubmed: 14645659
Neuroreport. 1998 Dec 1;9(17):3897-902
pubmed: 9875725
Neuroscience. 2006 Dec;143(3):671-8
pubmed: 17000053
Jpn J Pharmacol. 1998 Mar;76(3):297-304
pubmed: 9593223
J Neurochem. 2011 Jan;116(2):291-303
pubmed: 21070242
Behav Brain Res. 2021 Mar 5;401:113093
pubmed: 33359368
Behav Brain Res. 2003 Jun 16;142(1-2):175-9
pubmed: 12798279
Int J Neuropsychopharmacol. 2020 Nov 26;23(8):533-542
pubmed: 32619232
Pharmacol Biochem Behav. 2013 Nov;112:42-8
pubmed: 24036473
Psychopharmacology (Berl). 2014 Feb;231(4):787-800
pubmed: 24114428
Life Sci. 2000 Feb 18;66(13):1271-9
pubmed: 10737422
ACS Chem Neurosci. 2015 Jul 15;6(7):1259-70
pubmed: 26011730
Metab Brain Dis. 2017 Oct;32(5):1619-1625
pubmed: 28624893
J Pharmacol Exp Ther. 1998 Aug;286(2):913-24
pubmed: 9694950
Behav Pharmacol. 2010 Jul;21(4):353-8
pubmed: 20695034
Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
pubmed: 11888546
Theranostics. 2021 Sep 7;11(19):9296-9310
pubmed: 34646371
Psychopharmacology (Berl). 1997 Aug;132(3):255-60
pubmed: 9292625
Pharmacol Biochem Behav. 1999 Jun;63(2):279-84
pubmed: 10371657
Sci Rep. 2021 Sep 3;11(1):17690
pubmed: 34480046
J Autism Dev Disord. 2007 Jan;37(1):73-85
pubmed: 17195920
Prog Neuropsychopharmacol Biol Psychiatry. 1999 May;23(4):613-24
pubmed: 10390720
J Neurosci. 2003 Aug 20;23(20):7451-60
pubmed: 12930783
Behav Brain Res. 2008 Dec 16;195(1):198-213
pubmed: 18571247
Science. 2011 Jul 29;333(6042):637-42
pubmed: 21798952
Br J Pharmacol. 1995 Jun;115(4):622-8
pubmed: 7582481
Neurochem Int. 1991;18(1):1-15
pubmed: 20504669
Brain. 2003 May;126(Pt 5):1182-92
pubmed: 12690057
Neuropharmacology. 2021 Feb 1;183:107838
pubmed: 31693871
Science. 2013 Jun 7;340(6137):1243-6
pubmed: 23744950
Physiol Behav. 2000 Dec;71(5):551-7
pubmed: 11239674
Front Pharmacol. 2015 Sep 16;6:200
pubmed: 26441657
Neuropharmacology. 1994 Mar-Apr;33(3-4):393-402
pubmed: 7984277
Neuropharmacology. 1997 Aug;36(8):1089-97
pubmed: 9294974
Neuropharmacology. 1997 Feb;36(2):233-9
pubmed: 9144661
Pharmacol Biochem Behav. 2021 Jan;200:173076
pubmed: 33220385
Biol Psychiatry. 2014 Sep 1;76(5):405-11
pubmed: 24090791
J Comp Neurol. 2000 Feb 7;417(2):181-94
pubmed: 10660896
Eur J Pharmacol. 1987 Apr 7;136(1):1-9
pubmed: 3496228
Neuropsychopharmacology. 1999 Aug;21(2 Suppl):106S-115S
pubmed: 10432496
J Child Psychol Psychiatry. 1999 Sep;40(6):839-49
pubmed: 10509879
Pharmacol Biochem Behav. 2021 Oct;209:173243
pubmed: 34314738
Int J Neuropsychopharmacol. 2001 Dec;4(4):399-408
pubmed: 11806866
Behav Brain Res. 2019 Oct 17;372:112055
pubmed: 31233821
Brain Res Mol Brain Res. 1996 Mar;36(2):251-60
pubmed: 8965645
Synapse. 1996 Jul;23(3):164-73
pubmed: 8807744
Metab Brain Dis. 2017 Dec;32(6):1929-1934
pubmed: 28795258
Psychopharmacology (Berl). 1998 Oct;139(4):300-10
pubmed: 9809851

Auteurs

Bryan D Alvarez (BD)

Department of Psychology, California State University, San Bernardino, San Bernardino, CA, United States.
Department of Neuroscience, Ohio State University, Columbus, OH, United States.

Cassandra Cavazos (C)

Department of Psychology, California State University, San Bernardino, San Bernardino, CA, United States.

Cheyenne A Morales (CA)

Department of Psychology, California State University, San Bernardino, San Bernardino, CA, United States.

Shannon M Lopez (S)

Department of Psychology, California State University, San Bernardino, San Bernardino, CA, United States.

Dionisio A Amodeo (DA)

Department of Psychology, California State University, San Bernardino, San Bernardino, CA, United States.

Classifications MeSH